Rep. Norm Thurston — Voting Record

Utah House District 62 · complete roll-call record from le.utah.gov
← All votes

Bill

Pharmacy Pricing Amendments
Number
H.B. 527 (2026GS)
Sponsor
Rep. Hall, Katy
Final action
Governor Signed 3/19/2026
Outcome
Became law — signed by Gov. Spencer J. Cox

Summary

This bill amends provisions related to pharmacy benefits.

What it does

  • This bill:
  • defines terms;
  • amends provisions related to drug maximum allowable cost, including regarding lists, appeals, and claims;
  • specifies penalties; and
  • provides the Insurance Department rulemaking authority.

Every vote on this bill

2026-02-24House Comm - Substitute Recommendation
House Health and Human Services Committee
11-0-3not eligible / no record
2026-02-24House Comm - Favorable Recommendation
House Health and Human Services Committee
11-0-3not eligible / no record
2026-03-02Senate Comm - Favorable Recommendation
Senate Economic Development and Workforce Services Committee
2-1-3not eligible / no record
2026-03-06House/ concurs with Senate amendment
Senate President
66-1-8YEA
2026-03-06Senate/ substituted
Senate 2nd Reading Calendar
0-0-29not eligible / no record
2026-03-06Senate/ passed 2nd & 3rd readings/ suspension
Clerk of the House
24-0-5not eligible / no record
2026-02-27House/ substituted
House 3rd Reading Calendar for House bills
0-0-75not eligible / no record
2026-02-27House/ passed 3rd reading
Senate Secretary
62-1-12YEA

Bill text

enrolled version · official source
43
31A-46-102
31A-46-103
31A-46-303
31A-46-401
0
Pharmacy Pricing Amendments
2026 GENERAL SESSION
STATE OF UTAH
Chief Sponsor: Katy Hall
Senate Sponsor: Evan J. Vickers
LONG TITLE
General Description:
This bill amends provisions related to pharmacy benefits.
Highlighted Provisions:
This bill:
defines terms;
amends provisions related to drug maximum allowable cost, including regarding lists, 
appeals, and claims;
specifies penalties; and
provides the Insurance Department rulemaking authority.
Money Appropriated in this Bill:
None
Other Special Clauses:
None
Utah Code Sections Affected:
AMENDS:
31A-46-102
, as last amended by Laws of Utah 2025, Chapter 525
31A-46-303
, as last amended by Laws of Utah 2020, Chapters 198, 275
31A-46-401
, as enacted by Laws of Utah 2019, Chapter 241
ENACTS:
31A-46-103
, Utah Code Annotated 1953
Be it enacted by the Legislature of the state of Utah:
Section 1. Section 
31A-46-102
 is amended to read:
31A-46-102
. Definitions.
As used in this chapter:
(1)
"340B drug" means a drug purchased through the 340B drug discount program by a 
340B entity.
(2)
"340B drug discount program" means the 340B drug discount program described in 42 
U.S.C. Sec. 256b.
(3)
"340B entity" means:
(a)
an entity participating in the 340B drug discount program;
(b)
a pharmacy of an entity participating in the 340B drug discount program; or
(c)
a pharmacy contracting with an entity participating in the 340B drug discount 
program to dispense drugs purchased through the 340B drug discount program.
(4)
"Administrative fee" means any payment, other than a rebate, that a pharmaceutical 
manufacturer makes directly or indirectly to a pharmacy benefit manager.
(5)
"Allowable claim amount" means the amount paid by an insurer under the customer's 
health benefit plan.
(6)
"Contracting insurer" means an insurer with whom a pharmacy benefit manager 
contracts to provide a pharmacy benefit management service.
(7)
"Cost share" means the amount paid by an insured customer under the customer's health 
benefit plan.
(8)
"Direct or indirect remuneration" means any adjustment in the total compensation:
(a)
received by a pharmacy from a pharmacy benefit manager for the sale of a drug, 
device, or other product or service; and
(b)
that is determined after the sale of the product or service.
(9)
"Dispense" means the same as that term is defined in Section 
58-17b-102
.
(10)
"Drug" means the same as that term is defined in Section 
58-17b-102
.
(11)
"Insurer" means the same as that term is defined in Section 
31A-22-636
.
(12)
"Maximum allowable cost" means:
(a)
a maximum reimbursement amount for a group of pharmaceutically and 
therapeutically equivalent drugs; or
(b)
any similar reimbursement amount that is used by a pharmacy benefit manager to 
reimburse pharmacies for multiple source drugs.
(13)
"Medicaid program" means the same as that term is defined in Section 
26B-3-101
.
(14)
"Obsolete" means a product that may be listed in national drug pricing compendia but 
is no longer available to be dispensed based on the expiration date of the last lot 
manufactured.
(15)
"Patient counseling" means the same as that term is defined in Section 
58-17b-102
.
(16)
"Pharmacy acquisition cost" means the net amount that a pharmaceutical wholesaler 
charges for a pharmaceutical product.
(16)
(17)
"Pharmaceutical facility" means the same as that term is defined in Section 
58-17b-102
.
(17)
(18)
"Pharmaceutical manufacturer" means a pharmaceutical facility that 
manufactures prescription drugs.
(18)
(19)
"Pharmacist" means the same as that term is defined in Section 
58-17b-102
.
(19)
(20)
"Pharmacy" means the same as that term is defined in Section 
58-17b-102
.
(20)
(21)
"Pharmacy benefits management service" means any of the following services 
provided to a health benefit plan, or to a participant of a health benefit plan:
(a)
negotiating the amount to be paid by a health benefit plan for a prescription drug; or
(b)
administering or managing a prescription drug benefit provided by the health benefit 
plan for the benefit of a participant of the health benefit plan, including administering 
or managing:
(i)
an out-of-state mail service pharmacy;
(ii)
a specialty pharmacy;
(iii)
claims processing;
(iv)
payment of a claim;
(v)
retail network management;
(vi)
clinical formulary development;
(vii)
clinical formulary management services;
(viii)
rebate contracting;
(ix)
rebate administration;
(x)
a participant compliance program;
(xi)
a therapeutic intervention program;
(xii)
a disease management program; or
(xiii)
a service that is similar to, or related to, a service described in Subsection 
(20)(a)
 or this Subsection 
(20)(b)
.
(21)
(22)
"Pharmacy benefit manager" means a person licensed under this chapter to 
provide a pharmacy benefits management service.
(22)
(23)
"Pharmacy service" means a product, good, or service provided to an individual 
by a pharmacy or pharmacist.
(23)
(24)
"Pharmacy services administration organization" means an entity that contracts 
with a pharmacy to assist with third-party payer interactions and administrative services 
related to third-party payer interactions, including:
(a)
contracting with a pharmacy benefit manager on behalf of the pharmacy; and
(b)
managing a pharmacy's claims payments from third-party payers.
(24)
(25)
"Pharmacy service entity" means:
(a)
a pharmacy services administration organization; or
(b)
a pharmacy benefit manager.
(25)
(26)
"Prescription device" means the same as that term is defined in Section 
58-17b-102
.
(26)
(27)
"Prescription drug" means the same as that term is defined in Section 
58-17b-102
.
(27)
(28)
(a)
"Rebate" means a refund, discount, or other price concession that is paid by 
a pharmaceutical manufacturer to a pharmacy benefit manager based on a 
prescription drug's utilization or effectiveness.
(b)
"Rebate" does not include an administrative fee.
(28)
(29)
(a)
"Reimbursement report" means a report on the adjustment in total 
compensation for a claim.
(b)
"Reimbursement report" does not include a report on adjustments made 
pursuant to
 a 
pharmacy audit or reprocessing.
(29)
(30)
"Retail pharmacy" means the same as that term is defined in Section 
58-17b-102
.
(30)
(31)
"Sale" means a prescription drug or prescription device claim covered by a 
health benefit plan.
(31)
(32)
"Spread pricing" means the practice in which a pharmacy benefit manager 
charges a health benefit plan a different amount for pharmacist services than the amount 
the pharmacy benefit manager reimburses a pharmacy for pharmacist services.
(32)
(33)
"Wholesale acquisition cost" means the same as that term is defined in 42 U.S.C. 
Sec. 1395w-3a.
Section 2. Section 
31A-46-103
 is enacted to read:
31A-46-103
. Rulemaking.
In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the 
department may make rules to implement this chapter.
Section 3. Section 
31A-46-303
 is amended to read:
31A-46-303
. Insurer and pharmacy benefit management services -- Registration 
-- Maximum allowable cost -- Audit restrictions.
(1)
An insurer and an insurer's pharmacy benefit manager is subject to the pharmacy audit 
provisions of Section 
58-17b-622
.
(2)
A pharmacy benefit manager shall not use maximum allowable cost as a basis for 
reimbursement to a pharmacy unless:
(a)
the drug is listed as "A" or "B" rated in the most recent version of the United States 
Food and Drug Administration's approved drug products with therapeutic equivalent 
evaluations, also known as the "Orange Book," or has an "NR" or "NA" rating or 
similar rating by a nationally recognized reference; and
(b)
the drug is:
(i)
generally available for purchase in this state from a national or regional 
wholesaler; and
(ii)
not obsolete.
(3)
The maximum allowable cost may be determined using comparable and current data on 
drug prices obtained from multiple nationally recognized, comprehensive data sources, 
including wholesalers, drug file vendors, and pharmaceutical manufacturers for drugs 
that are available for purchase by pharmacies in the state.
(4)
For every drug for which the pharmacy benefit manager uses maximum allowable cost 
to reimburse a contracted pharmacy, the pharmacy benefit manager shall:
(a)
make a list available to a network pharmacy upon request in a format that:
(i)
is electronic;
(ii)
is computer accessible and searchable;
(iii)
identifies all drugs for which maximum allowable costs have been established; 
and
(iv)
for each drug specifies:
(A)
the national drug code; and
(B)
the maximum allowable cost;
(b)
include in the contract with the pharmacy information identifying the national drug 
pricing compendia and other data sources used to obtain the drug price data;
(b)
(c)
review and make necessary adjustments to the maximum allowable cost, using 
the most recent data sources identified in Subsection 
(4)(a)
(4)(b)
, at least once per 
week;
(c)
(d)
provide a process for the contracted pharmacy to appeal the maximum allowable 
cost in accordance with Subsection 
(5)
; and
(d)
(e)
include in each contract with a contracted pharmacy a process to obtain an 
update to the pharmacy product pricing files used to reimburse the pharmacy in a 
format that is readily available and accessible.
(5)
(a)
The right to appeal in Subsection 
(4)(c)
(4)(d)
 shall be:
(i)
limited to 21 days following the initial claim adjudication; and
(ii)
investigated and resolved by the pharmacy benefit manager within 14 business 
days.
(b)
A pharmacy benefit manager shall:
(i)
provide as part of the appeals process:
(A)
a dedicated telephone number, electronic mail address, and website for the 
purpose of submitting appeals; and
(B)
the ability for a pharmacy to submit an appeal directly to the pharmacy benefit 
manager or through the pharmacy's pharmacy services administrative 
organization; and
(ii)
allow a pharmacy to submit documentation in support of the pharmacy's appeal 
on paper or electronically.
(c)
If an appeal is denied, the pharmacy benefit manager shall provide the contracted 
pharmacy
 with
:
(i)
the reason for the denial
 and
;
(ii)
the identification of the national drug code of the drug that may be purchased by 
the pharmacy at a price at or below the price determined by the pharmacy benefit 
manager
.
; and
(iii)
the specific basis upon which the pharmacy benefit manager can show that the 
drug is available for purchase at or below the maximum allowable cost.
(d)
If an appeal is upheld or the pharmacy benefit manager cannot show the drug is 
available for purchase at or below the maximum allowable cost for a similarly 
situated pharmacy as the pharmacy that submitted the appeal, the pharmacy benefit 
manager shall:
(i)
make an adjustment for the pharmacy that appealed;
(ii)
permit the dispensing pharmacy to reverse the claim and resubmit an adjusted 
claim without an additional charge; and
(iii)
consider additional action consistent with the outcome of the appeal.
(6)
The contract with each pharmacy shall contain a dispute resolution mechanism in the 
event either party breaches the terms or conditions of the contract.
(7)
This section does not apply to a pharmacy benefit manager when the pharmacy benefit 
manager is providing pharmacy benefit management services on behalf of the Medicaid 
program.
Section 4. Section 
31A-46-401
 is amended to read:
31A-46-401
. Penalties.
A person that violates a provision of this chapter is subject to the penalties 
described in Section 
31A-2-308
.
(1)
The commissioner may order a pharmacy benefit manager who violates this chapter to 
forfeit to the state not more than $2,500 for each violation.
(2)
Each day the violation continues is a separate violation.
Section 5. 
Effective Date.
This bill takes effect on 
May 6, 2026
.
3-12-26 9:07 AM